Genetically engineered vaccinia viruses
AssigneesNational University Corporation Tottori University, Astellas Pharma Inc.
InventorsShinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
Life of this patent
Estimating the term…
Abstract
The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
Claims25
A vaccinia virus comprising a polynucleotide encoding interleukin-7(IL-7);
- and a polynucleotide encoding interleukin-12(IL-12), wherein the vaccinia virus is deficient in the function of vaccinia virus growth factor (VGF) or deficient in the function of O1L, and wherein the vaccinia virus is oncolytic against human cancer cells.
A combination kit comprising:
- a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12, wherein the vaccinia viruses are deficient in the function of VGF or deficient in the function of O1L, and wherein the vaccinia viruses in combination are oncolytic against human cancer cells.
Dependencies are inferred from the claim text.